Susquehanna International Group
HRTX icon

Susquehanna International Group’s Heron Therapeutics HRTX Stock Holding History

Susquehanna International Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$231K Sell
288,253
-51,993
-15% -$60.2K ﹤0.01% 11431
2025
Q4 		$442K Buy
340,246
+11,279
+3% +$13.9K ﹤0.01% 9091
2025
Q3 		$414K Sell
328,967
-103,069
-24% -$163K ﹤0.01% 9396
2025
Q2 		$894K Buy
432,036
+232,655
+117% +$475K ﹤0.01% 7717
2025
Q1 		$439K Buy
199,381
+141,070
+242% +$274K ﹤0.01% 9184
2024
Q4 		$89.2K Sell
58,311
-68,806
-54% -$112K ﹤0.01% 11418
2024
Q3 		$253K Sell
127,117
-191,595
-60% -$457K ﹤0.01% 9982
2024
Q2 		$1.12M Buy
318,712
+132,814
+71% +$408K ﹤0.01% 6327
2024
Q1 		$515K Buy
185,898
+116,673
+169% +$293K ﹤0.01% 8435
2023
Q4 		$118K Sell
69,225
-114,617
-62% -$126K ﹤0.01% 11198
2023
Q3 		$189K Sell
183,842
-177,542
-49% -$253K ﹤0.01% 10289
2023
Q2 		$419K Buy
361,384
+32,709
+10% +$58.3K ﹤0.01% 8726
2023
Q1 		$496K Sell
328,675
-6,852
-2% -$17.2K ﹤0.01% 8585
2022
Q4 		$839K Buy
335,527
+10,350
+3% +$33.3K ﹤0.01% 6566
2022
Q3 		$1.37M Buy
325,177
+71,289
+28% +$279K ﹤0.01% 5809
2022
Q2 		$708K Sell
253,888
-142,778
-36% -$573K ﹤0.01% 7391
2022
Q1 		$2.27M Buy
396,666
+130,178
+49% +$953K ﹤0.01% 5189
2021
Q4 		$2.43M Buy
266,488
+73,359
+38% +$749K ﹤0.01% 5050
2021
Q3 		$2.06M Buy
193,129
+35,909
+23% +$437K ﹤0.01% 5764
2021
Q2 		$2.44M Sell
157,220
-36,535
-19% -$581K ﹤0.01% 5471
2021
Q1 		$3.14M Buy
193,755
+73,978
+62% +$1.32M ﹤0.01% 4856
2020
Q4 		$2.54M Buy
119,777
+43,406
+57% +$754K ﹤0.01% 4602
2020
Q3 		$1.13M Sell
76,371
-70,196
-48% -$1.1M ﹤0.01% 5804
2020
Q2 		$2.16M Sell
146,567
-183,488
-56% -$3.01M ﹤0.01% 4358
2020
Q1 		$3.88M Buy
330,055
+227,386
+221% +$4.27M ﹤0.01% 2907
2019
Q4 		$2.41M Sell
102,669
-83,660
-45% -$1.85M ﹤0.01% 4018
2019
Q3 		$3.45M Buy
186,329
+43,745
+31% +$805K ﹤0.01% 3275
2019
Q2 		$2.65M Sell
142,584
-55,244
-28% -$1.1M ﹤0.01% 3660
2019
Q1 		$4.83M Buy
197,828
+165,921
+520% +$4.34M ﹤0.01% 2497
2018
Q4 		$828K Sell
31,907
-1,990
-6% -$54.7K ﹤0.01% 5046
2018
Q3 		$1.07M Sell
33,897
-72,439
-68% -$2.7M ﹤0.01% 5082
2018
Q2 		$4.13M Buy
106,336
+61,511
+137% +$1.96M ﹤0.01% 2960
2018
Q1 		$1.24M Sell
44,825
-214,557
-83% -$4.87M ﹤0.01% 4811
2017
Q4 		$4.7M Sell
259,382
-75,545
-23% -$1.23M ﹤0.01% 2605
2017
Q3 		$5.41M Sell
334,927
-235,417
-41% -$3.69M ﹤0.01% 2403
2017
Q2 		$7.9M Buy
+570,344
New +$8.26M ﹤0.01% 1899
2017
Q1 		– Sell
-485,927
Closed -$6.73M – 9352
2016
Q4 		$6.37M Buy
485,927
+321,445
+195% +$5.04M ﹤0.01% 2069
2016
Q3 		$2.83M Buy
164,482
+49,963
+44% +$927K ﹤0.01% 3001
2016
Q2 		$2.07M Sell
114,519
-55,375
-33% -$1.08M ﹤0.01% 3515
2016
Q1 		$3.23M Sell
169,894
-31,838
-16% -$628K ﹤0.01% 2953
2015
Q4 		$5.39M Sell
201,732
-225,056
-53% -$6.02M ﹤0.01% 2440
2015
Q3 		$10.4M Sell
426,788
-466,231
-52% -$15.5M ﹤0.01% 1786
2015
Q2 		$27.8M Buy
893,019
+752,618
+536% +$14.2M 0.01% 1040
2015
Q1 		$2.04M Buy
140,401
+94,723
+207% +$1.07M ﹤0.01% 4286
2014
Q4 		$460K Buy
+45,678
New +$373K ﹤0.01% 7371
2014
Q3 		– Sell
-379,946
Closed -$4.68M – 9634
2014
Q2 		$4.68M Buy
+379,946
New +$4.54M ﹤0.01% 3191

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Susquehanna International Group's HRTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Heron Therapeutics (HRTX) stake by 15% in Q1 2026, selling an estimated $60.2K and leaving 288,253 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #11431.

Susquehanna International Group first reported a position in HRTX in Q2 2014 and has held it in 46 quarters since. The position peaked at $27.8M in Q2 2015. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Susquehanna International Group held 288,253 shares of Heron Therapeutics worth $231K as of Q1 2026.
  • Susquehanna International Group sold 51,993 Heron Therapeutics shares in Q1 2026, an estimated $60.2K.
  • Heron Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11431 holding.
  • Susquehanna International Group first reported a position in Heron Therapeutics in Q2 2014 and has held it in 46 quarters since.
  • Susquehanna International Group's Heron Therapeutics position peaked at $27.8M in Q2 2015.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.